



Clinical Laserthermia Systems announces that the date for conversion of interim shares is estimated to February 21, 2024

Lund, Sweden - Today, February 14, 2024, Clinical Laserthermia Systems AB ("CLS" or the "Company") announces that 189,182,414 new B-shares have been registered with the Swedish Companies Registration Office, as a result of the exercise of warrants of series TO 6 B ("TO 6 B").

Conversion of interim shares to ordinary B-shares takes place around February 21, 2024, and are expected to be available on each subscriber's account around February 23, 2024. The total number of shares in the Company as a result of the warrant exercise of TO 6 B and the directed new share issue to underwriters in connection with TO 6 B amount to 1,570,341,299, of which 600,000 A-shares and 1,569,741,299 B-shares, and the share capital will amount to approximately SEK 18,134,146.

Advisors

In connection with the exercise of warrants of series TO 6 B, Sedermera Corporate Finance AB and Redeye AB are Joint Lead Managers. Markets & Corporate Law Nordic AB is legal advisor and Nordic Issuing AB acts as issuing agent.

For more information about the warrants of series TO 6 B, please contact:

Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
Website: www.sedermera.se

Redeye AB
Phone: +46 (0)8 545 013 30
E-mail: info@redeye.se
Website: www.redeye.se

For more information about CLS, please contact:

Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
Website: www.clinicallaser.se

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se